Por: Los Angeles Times Business May 16, 2023
The Federal Trade Commission sued Tuesday to block Amgen's $27.8-billion deal to buy Horizon Therapeutics, arguing the tie-up would stifle competition for the development of treatments for serious illnesses. In a sealed complaint filed in Illinois federal court, the FTC said the acquisition would allow Amgen to entrench Horizon’s monopoly on medications for thyroid eye disease and chronic refractory gout. The complaint seeks an injunction... + full article
Fox Business USA Business May 17, 2023
MRC President and founder Brent Bozell discusses the FTC's artificial intelligence regulations and reacts to Biden using a cheat sheet during a press conference. The Federal Trade Commission (FTC) said Tuesday it will sue to stop Amgen’s $27.8 billion acquisition of... + más
Amgen to buy Horizon Therapeutics in $26.4B deal | Associated Press
US sues to block Amgen’s $27.8 billion takeover of Horizon Therapeutics | The Boston Globe
ABC News USA Business May 16, 2023
The U.S. is attempting to block the proposed acquisition of Horizon Therapeutics for more than $26 billion by biotech drug developer Amgen on antitrust grounds. The Federal Trade Commission said Tuesday that the deal, announced in December, would give Amgen unfair leverage to... + más
Monopoly concerns push FTC to sue to block Amgen's more than $26B deal for Horizon | ABC News
Monopoly concerns push FTC to sue to block Amgen's more than $26B deal for Horizon | Associated Press
ABC News USA Health May 16, 2023
Associated Press USA Health May 16, 2023
The Hill USA Politics May 16, 2023
Associated Press USA Business December 12, 2022
Amgen is spending more than $26 billion to dive deeper into rare disease treatments with a deal for drugmaker Horizon Therapeutics. The biotech drug developer said Monday that it will pay $116.50 in cash for each share of Horizon, which makes a thyroid eye disease treatment that... + más
Amgen to buy Horizon Therapeutics in $26.4B deal | 10 WBNS
Amgen to buy Horizon Therapeutics in $26.4B deal | ABC News
10 WBNS USA Health December 12, 2022
LOS ANGELES — Amgen will acquire Horizon Therapeutics, a biopharmaceutical company that focuses on treatments for rare, autoimmune diseases, for about $26.4 billion. Each Horizon shareholder will receive $116.50 per share for each share they own. The deal has an enterprise... + más
About iurex | Privacy Policy | Disclaimer |